Parkinson’s disease: From human genetics to clinical trials-Reference-Cited by-同舟云学术

Parkinson’s disease: From human genetics to clinical trials

Published:2015-09-16 Issue:305 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

van der Brug Marcel P.¹,Singleton Andrew²,Gasser Thomas³,Lewis Patrick A.⁴⁵⁶

Affiliation:

1. Department of Diagnostics Discovery, Genentech, South San Francisco, CA 94080, USA.

2. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.

3. Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen and German Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

4. School of Pharmacy, University of Reading, Reading RG6 6AP, UK.

5. Centre for Integrated Neuroscience and Neurodynamics, University of Reading, Reading RG6 6AP, UK.

6. Department of Molecular Neuroscience, UCL Institute of Neurology, Queen’s Square, London WC1N 3BG, UK.

Abstract

In this Perspective, van der Brug and colleagues discuss the road from elucidating the genetics of Parkinson's disease through drug discovery to clinical trials, mapping the challenges along the way.

Funder

Parkinson's UK

Wellcome Trust/Medical Research Council (MRC) Joint Call in Neurodegeneration

MRC

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference68 articles.

1. Parkinson's disease

2. The current and projected economic burden of Parkinson's disease in the United States

3. Therapies in Parkinsonʼs disease